Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20022946 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Soliman GA, et al. (2010) mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285, 7866-79 20022946
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T37-p - 4E-BP1 (human) ▲
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin no change compared to control
Torin1 decrease

T46-p - 4E-BP1 (human) ▲
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin no change compared to control
Torin1 decrease

S473-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin no effect upon treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
serum increase
EGF no change compared to control
phorbol ester no change compared to control

T183-p - AMPKA1 (human) ▲
Orthologous residues
AMPKA1 (human): T183‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
2-deoxyglucose increase

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin no change compared to control
serum increase
EGF increase
phorbol ester increase

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin no change compared to control
serum increase
EGF increase
phorbol ester increase

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin no change compared to control
serum increase
EGF increase
phorbol ester increase

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin no change compared to control
serum increase
EGF increase
phorbol ester increase

S2481-p - mTOR (human) ▲
Orthologous residues
mTOR (human): S2481‑p, mTOR (mouse): S2481‑p, mTOR (rat): S2481‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE mTOR (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE mTOR (human) transfection of inactive enzyme, pharmacological activator of upstream enzyme, phospho-antibody, activation of upstream enzyme, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase mTORC1-associated; no rapamycin effect on mTORC2-associated mTOR
wortmannin insulin inhibit treatment-induced increase
decrease torin1
rapamycin no effect upon treatment-induced increase mTORC2, IP Rictor
rapamycin no change compared to control whole cell lysates (WCL)
no change compared to control torin1, whole cell lysates
serum increase
serum withdrawal decrease
amino acids increase IP Raptor
amino acids no change compared to control WCL
amino acid starvation decrease IP Raptor
amino acid starvation no change compared to control WCL
2-deoxyglucose decrease IP Raptor and WCL
EGF increase
phorbol ester increase
raptor (human) no change compared to control
RHEB (human) raptor (human) increase
insulin raptor (human) increase
rapamycin raptor (human), RHEB (human) inhibit treatment-induced increase
mTOR (human) raptor (human), RHEB (human) inhibit treatment-induced increase mTor kinase-dead
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T412-p - p70S6K (human) ▲
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293 (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
2-deoxyglucose decrease
serum increase
phorbol ester increase
mTOR (human), raptor (human) increase slight increase
RHEB (human) mTOR (human), raptor (human) augment treatment-induced increase
insulin mTOR (human), raptor (human) augment treatment-induced increase
rapamycin mTOR (human), raptor (human), RHEB (human) inhibit treatment-induced increase
RHEB (human) mTOR (human), raptor (human) decrease Kinase dead mTOR

T36-p - 4E-BP1 (mouse) ▲
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease
Torin1 decrease

T45-p - 4E-BP1 (mouse) ▲
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease
Torin1 decrease

S473-p - Akt1 (mouse) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin no effect upon treatment-induced increase
wortmannin insulin inhibit treatment-induced increase
TSC1 (mouse) no change compared to control
insulin TSC1 (mouse) no change compared to control
rapamycin insulin TSC1 (mouse) no change compared to control
wortmannin insulin TSC1 (mouse) no change compared to control

S2481-p - mTOR (mouse) ▲
Orthologous residues
mTOR (human): S2481‑p, mTOR (mouse): S2481‑p, mTOR (rat): S2481‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE mTOR (mouse) genetic knockout/knockin of upstream enzyme, pharmacological activator of upstream enzyme, activation of upstream enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase mTORC1-associated mTOR; no rapamycin effect in mTORC2-associated mTOR
wortmannin insulin inhibit treatment-induced increase mTORC1 and mTORC2 associated
rapamycin decrease
Torin1 decrease
amino acids increase
insulin amino acids augment treatment-induced increase
rapamycin amino acids, insulin inhibit treatment-induced increase
wortmannin amino acids, insulin inhibit treatment-induced increase
amino acid starvation decrease
2-deoxyglucose no change compared to control
TSC1 (mouse) decrease hamartin -/- increases
insulin TSC1 (mouse) increase
rapamycin insulin TSC1 (mouse) inhibit treatment-induced increase
wortmannin insulin TSC1 (mouse) inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

T412-p - p70S6K (mouse) ▲
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase
amino acids, insulin increase
rapamycin amino acids, insulin inhibit treatment-induced increase
wortmannin amino acids, insulin inhibit treatment-induced increase
amino acid starvation decrease
2-deoxyglucose decrease
TSC1 (mouse) decrease hamartin -/- increase
insulin increase
insulin TSC1 (mouse) increase
rapamycin insulin TSC1 (mouse) inhibit treatment-induced increase
wortmannin insulin TSC1 (mouse) inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.